Vanda Pharmaceuticals (VNDA) Q3 Results Meet Revenue Growth But Cash Burn Lingers

Vanda Pharmaceuticals entered this Q3 2026 report out of favour, with the share price down about 20% over the past three months and trading on a low 1.1x price-to-sales multiple. The headline today is clear: revenue for the quarter came in at US$69.8m while the business still posted a net loss of US$22.6m.

The stock barely moved on the day, rising just 1.3%. That muted reaction contrasts with the improvement in quarterly revenue and the smaller loss, suggesting investors are still focused on cash runway concerns rather than the shift in operating performance.

Love the revenue progress at Vanda Pharmaceuticals but concerned about the ongoing losses and cash runway questions? Check out the list of solid balance sheet and fundamentals stocks (22 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$69.8m vs. US$56.3m (up about 24%)
• Net Loss (Q3 2026 vs. Q3 2025): US$22.6m loss vs. US$22.6m loss (broadly flat year on year)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.37 loss per share vs. US$0.38 loss per share (slightly smaller loss per share)
• Trailing 12-Month Net Loss (Q3 2026 TTM vs. Q3 2025 TTM): US$274.8m loss vs. US$84.2m loss (much larger twelve month loss)

Tired of wading through dense earnings reports and long tables of figures? Get a clear, visual view of Vanda Pharmaceuticals with an at a glance look at its recent financials and cash burn in the company report for Vanda Pharmaceuticals..

Evaluating Whether Vanda’s Growth Engine Is Firing Yet

Bullish analysts argue that Vanda Pharmaceuticals can build a sturdier revenue mix around psychiatry and rare-disease launches.

"Bullish analysts expect Vanda Pharmaceuticals to use growing Fanapt prescriptions, the planned BYSANTI launch, and new products like NEREUS to offset HETLIOZ erosion and build a broader CNS and rare-disease revenue base."

The latest quarter gives that view some traction. Fanapt prescriptions and sales are rising, NEREUS already contributes US$1.6m and showed more than 100% TRx growth, and BYSANTI is approved with launch slated for Q4 2026. At the same time, HETLIOZ still contributes US$21.7m, so diversification is progressing but not yet fully tested against deeper erosion.

The price and this Narrative do not agree. → Uncover what this Narrative says Vanda Pharmaceuticals is actually worth.

Vanda Bear Case: Cash Burn Fears Still Linger

The cautious view says Vanda Pharmaceuticals is stuck spending heavily while its newer products fail to carry enough weight.

"While management guides to operating expense moderation beginning by late 2026 and more materially in 2027, reported operating expenses of US$367.3 million in 2025 and US$216.3 million in the first half of 2026, combined with an expectation that 2026 cash burn will exceed 2025, point to the possibility that spending remains elevated for longer."

Q3 brings a mixed scorecard. Operating expenses fell 18% sequentially, which directly challenges the idea that spending cannot bend down. Yet net loss for the first nine months of 2026 widened to US$133.6m, and management still expects 2026 cash burn to exceed 2025. The cost curve is finally pointing in the right direction, but the cash drain that underpins the bearish argument has not cleared.

Hunt For Mispriced Growth Stories

Vanda Pharmaceuticals reported changes in revenue and costs, yet the share price showed little immediate reaction. The real opportunity could be researching stocks that appear undervalued before any valuation gap potentially narrows.

• Company 1 - 16% below our estimate - expand photonics manufacturing lines to support AI data center and advanced packaging demand.
• Company 2 - 43% below our estimate - connect multinational merchants to local cards, wallets and payout options in expanding digital commerce.
• Company 3 - 40% below our estimate - scale coconut based beverages into mainstream distribution while adding private label volumes with large retailers.

Those are three of them. See all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com